Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies

France Nouvelles Nouvelles

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
France Dernières Nouvelles,France Actualités
  • 📰 Nature
  • ⏱ Reading Time:
  • 24 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 13%
  • Publisher: 68%

Nature research paper: Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies

and is provided in this format here as a response to the exceptional public-health crisis. This accepted manuscript will continue through the processes of copy editing and formatting to publication of a finalized version of record on nature.com. Please note there may be errors present in this version, which may affect the content, and all legal disclaimers apply.

The SARS-CoV-2 B.1.1.529 variant contains 15 mutations on the receptor-binding domain . How Omicron would evade RBD neutralizing antibodies requires immediate investigation. Here, we used high-throughput yeast display screeningto determine the RBD escaping mutation profiles for 247 human anti-RBD NAbs and showed that the NAbs could be unsupervised clustered into six epitope groups , which is highly concordant with knowledge-based structural classifications.

Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite:

Nature /  🏆 64. in US

France Dernières Nouvelles, France Actualités

Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.

SARS-CoV-2 infection in free-ranging white-tailed deer - NatureNature - <ArticleTitle Language="En" xml:lang="en">SARS-CoV-2 infection in free-ranging white-tailed deer</ArticleTitle>
Lire la suite »

A new tool to probe SARS-CoV-2 variantsA new tool to probe SARS-CoV-2 variantsVirus-like particles offer a new way to investigate genetic variation in SARSCoV2. Learn more in a new SciencePerspective:
Lire la suite »

An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19A new Science study details PF-07321332, an orally active, small-molecule inhibitor of the SARSCoV2 main protease, a key viral target. In a phase I clinical trial, it achieved concentrations expected to inhibit the virus based on in vitro studies. pfizer
Lire la suite »

A new tool to probe SARS-CoV-2 variantsA new tool to probe SARS-CoV-2 variantsVirus-like particles offer a new way to investigate genetic variation in SARSCoV2. Learn more in a new SciencePerspective:
Lire la suite »

5 Texas monoclonal infusion centers run out of only antibody treatment for COVID omicron variant5 Texas monoclonal infusion centers run out of only antibody treatment for COVID omicron variantAUSTIN – Five of the state’s infusion centers have run out of the antibody therapy used to treat the omicron variant of the coronavirus, which is now the...
Lire la suite »

Antibody Infusion Centers In 5 Texas Cities Temporarily Run Out Of Treatment For Omicron VariantAntibody Infusion Centers In 5 Texas Cities Temporarily Run Out Of Treatment For Omicron VariantTexas Department of Health and Human Services says the treatment cannot be offered until January, when the next shipment of the drug is expected to arrive from the federal government.
Lire la suite »



Render Time: 2025-04-20 02:33:11